Atea Pharmaceuticals stock
AVIRNASDAQAtea Pharmaceuticals, Inc., HealthcareISIN US04683R1068
35Score 35 out of 100, Weak
Price and trend
45 / 100
Price history
+20% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 15% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 56).
The price is 32% below its 52-week high. Largest decline in 6 years: 97% (February 2021 to May 2025).
Chart figures for advanced users
- SMA 50$4.83
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$4.95
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)56
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.96
- The lowest closing price of the last twelve months.
- Resistance$6.15
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Atea Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $338.08M, is number 275 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 35 out of 100 (Weak): rank 604 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $301.83M, financial debt $843K.Stability 77
Weaknesses
- Loss-makingLoss of $158.35M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$132.03M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 52% a year over the last 12 months.
Its standout strength is stability, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 4 Mar 2027in 111 days
- Last reported
- 9 Nov 2026EPS reported −$0.40 (expected −$0.51)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.990.0%
- Revenue
- $5.74M0.0%
- Earnings per share
- −$1.480.0%
- Revenue
- $30M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +0.4%No change stated: cash runway extends through 2027, top-line results expected in early Q1 2027 and launch in mid 2028.
“We completed patient enrollment for C-FORWARD in June, and top line results are expected in early Q1 27.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 12 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $25,446 in total.
- Murphy Polly A.Purchase
18 May 2026, Board
- Shares
- 6,100
- Price
- $4.17
- Value
- $25,446
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Atea Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 35
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- AlectorALEC $364.75M71
- C4 TherapeuticsCCCC $363.75M34
- Sagimet BiosciencesSGMT $356.12M45
- PepGenPEPG $348.61M42
- Opus GeneticsIRD $337.77M42
- Editas MedicineEDIT $330.29M25
- Eikon TherapeuticsEIKN $327M33
- Enanta PharmaceuticalsENTA $326.2M27
ETFs that hold Atea Pharmaceuticals
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.02% | 0.35% | €1.25B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 27 Feb 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.